Adverum Biotechnologies

$13.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.40 (-2.81%) Today
$0.00 (0.00%) As of 10:14 PM UTC after-hours

Why Robinhood?

You can buy or sell ADVM and other stocks, options, and ETFs commission-free!

About ADVM

Adverum Biotechnologies, Inc. Common Stock, also called Adverum Biotechnologies, is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA. The listed name for ADVM is Adverum Biotechnologies, Inc. Common Stock.

CEO
Laurent Fischer
Employees
114
Headquarters
Redwood City, California
Founded
2006
Market Cap
1.11B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.10M
High Today
$14.37
Low Today
$13.77
Open Price
$14.15
Volume
499.84K
52 Week High
$26.98
52 Week Low
$7.36

Collections

ADVM Earnings

-$0.36
-$0.24
-$0.12
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, After Hours

You May Also Like